TCGA-OR-A5JO-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.561
- INTERFERON_GAMMA_RESPONSE+0.549
- IL6_JAK_STAT3_SIGNALING+0.535
- INFLAMMATORY_RESPONSE+0.522
- TNFA_SIGNALING_VIA_NFKB+0.509
- INTERFERON_ALPHA_RESPONSE+0.489
- IL2_STAT5_SIGNALING+0.421
- COAGULATION+0.412
- COMPLEMENT+0.397
- APOPTOSIS+0.353
Top 10 suppressed
- MYC_TARGETS_V2-0.489
- OXIDATIVE_PHOSPHORYLATION-0.392
- E2F_TARGETS-0.391
- G2M_CHECKPOINT-0.385
- MYC_TARGETS_V1-0.319
- MTORC1_SIGNALING-0.313
- UNFOLDED_PROTEIN_RESPONSE-0.236
- SPERMATOGENESIS-0.192
- PROTEIN_SECRETION-0.186
- UV_RESPONSE_UP-0.175
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088910 | — | — | 0.930 |
| 2 | TCGA-L9-A743-01A-43R-A39D-07 | — | cohortA1 | 0.928 |
| 3 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.914 |
| 4 | C3N-02923 | — | cohortMD2 | 0.914 |
| 5 | SRR10842349 | — | — | 0.911 |
| 6 | BS_RGPSEMHC | Posterior Fossa Ependymoma | — | 0.910 |
| 7 | SRR5088860 | — | — | 0.909 |
| 8 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.907 |
| 9 | SRR22247245 | — | cohortMD2 | 0.907 |
| 10 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.561 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.549 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.535 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.522 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.509 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.489 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.421 | Idelalisib | — uncovered |
| COAGULATION | 0.412 | Binimetinib | — uncovered |
| COMPLEMENT | 0.397 | Inavolisib | — uncovered |
| APOPTOSIS | 0.353 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.332 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.282 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.191 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.155 | Idelalisib | — uncovered |
| HYPOXIA | 0.136 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.102 | Inavolisib | — uncovered |